Skip to main content
Sanjay Goel, MD, Oncology, Bronx, NY

SanjayGoelMD, MS

Oncology Bronx, NY

Gastrointestinal Cancer, Clinical Pharmacology

Professor, Medicine, Rutgers Cancer Institute of New Jersey

Dr. Goel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Goel's full profile

Already have an account?

  • Office

    AECOM
    1825 Eastchester Rd
    Bronx, NY 10461
    Phone+1 718-904-2488
    Fax+1 718-904-2830

Education & Training

  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineM.S., Clinical Research Methodology, 2001 - 2003
  • Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)
    Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2000 - 2002
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineFellowship, Hematology, Oncology, 2000 - 2002
  • University of Colorado
    University of ColoradoFellowship, Hematology and Medical Oncology, 1999 - 2000
  • University of Colorado Health Sciences Center
    University of Colorado Health Sciences CenterFellowship, Hematology, Oncology, 1999 - 2000
  • SUNY Downstate Health Sciences University
    SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1996 - 1999
  • Christian Medical College Vellore
    Christian Medical College VelloreClass of 1995

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2002 - 2026
  • NJ State Medical License
    NJ State Medical License 2022 - 2025
  • VA State Medical License
    VA State Medical License 2002 - 2008
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Translational Research Award ECOG Young Investigators Symposium, 2007
  • Best Faculty Teaching 2005
  • Best Presentation Glaxo Smith-Kline National Oncology Fellows Forum, 2002
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case For Prophylaxis.  
    Swami U, Goel S, Mani S, Curr Drug Targets, 4/15/2013
  • Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy.  
    Aparo S, Goel S, Crit Rev Oncol Hematol, 7/1/2012
  • Eribulin-A review of preclinical and clinical studies.  
    Swami U, Chaudhary I, Ghalib MH, Goel S, Crit Rev Oncol Hematol, 2/1/2012
  • Join now to see all

Abstracts/Posters

  • Tumor Biology
    Goel S, 47th Annual Meeting of the American Society of Clinical Oncology, 6/1/2011
  • “PIK3CA/PTEN mutation status predicts response of the colon cancer cells to the EGFR inhibitor cetuximab”
    Goel S, Jhawer M, Wilson AJ, et al, 2007 ECOG Young Investigators Symposium in Fort Lauderdale, FL, 1/1/2007
  • Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamcis of Ixabepilone.
    Goel S, Goldberg G, Iacono L, et al, ASCO Annual Meeting Proceedings Part I, 6/20/2006
  • Join now to see all

Lectures

  • Assessing Response to Therapy: Radiographic Response Criteria Review 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
  • Colorectal Cancer: Updates and Future Directions 
    Department of Pathology, Assam Medical College, Dibrugah, Assam, India - 10/1/2010
  • Updates in Colorectal Cancer 
    Grand Rounds, Department of Surgery, Montefiore Medical Center, Albert Einstein College of Medicine - 12/1/2006
  • Join now to see all

Press Mentions

  • Neil Palmisiano, MD, Appointed as Deputy Director of Phase 1 Therapeutics for Hematologic Malignancies at Rutgers Cancer Institute of New Jersey
    Neil Palmisiano, MD, Appointed as Deputy Director of Phase 1 Therapeutics for Hematologic Malignancies at Rutgers Cancer Institute of New JerseyOctober 3rd, 2022
  • Benefit of Biologic Agents in mCRC Is Color-Blind
    Benefit of Biologic Agents in mCRC Is Color-BlindDecember 16th, 2021
  • Black Family Cancer Awareness Week Blog Q&A
    Black Family Cancer Awareness Week Blog Q&AJune 16th, 2021
  • Join now to see all

Professional Memberships